Life sciences companies collecting gender identity data in clinical trials and patient programs face legal and financial risks if they mishandle the information.
Pharmaceutical and medical device firms gather this data to improve representation, meet regulatory expectations, or refine direct-to-patient marketing. Modern privacy laws classify gender identity as sensitive information. Errors in collection, storage, or use can result in regulatory fines, lawsuits, reputational harm, and investor scrutiny.
How privacy laws treat gender identity
The European Union’s General Data Protection Regulation applies to some U.S.-based activities and protects “special categories” of personal data, including health, sexual orientation, and biometric details. It recognizes that individuals may express a gender identity different from their sex assigned at birth. Failing to accurately record or process this information can violate the regulation’s principle of data accuracy.
In the U.S., state laws create additional risks. California’s Privacy Rights Act expanded the state’s consumer privacy law to cover “sensitive personal information,” which includes sexual orientation and related identity markers. Consumers can limit how businesses use this data, restricting it to only what’s necessary to provide expected services. The California attorney general has enforced these rules aggressively, and similar laws exist in Virginia, Colorado, and other states.
Firms operating across multiple jurisdictions may face scrutiny from several regulators simultaneously.
Related: National Interest Waivers Demystified: A Complete Guide to the Process
Discrimination claims add another layer of risk
Mishandling gender identity data can also lead to discrimination claims. Common issues in the life sciences industry include:
- Scope creep and reuse: Clinical trial sponsors might collect gender identity data for inclusion tracking but later use it for targeted marketing without consent. Vendors may also repurpose the data for unrelated analytics, which can be framed as profiling or discrimination.
- Tokenism in research: Claiming a clinical trial includes transgender participants without conducting meaningful subgroup analysis or including relevant endpoints can create legal and reputational problems. Plaintiffs may argue the data was collected under false pretenses, exposing companies to allegations of deceptive practices.
These risks are not hypothetical. Privacy claims are often combined with discrimination and emotional distress allegations, creating a complex legal environment for unprepared companies.
The stakes are particularly high for life sciences firms because their work often involves FDA oversight. A privacy error can escalate into broader regulatory scrutiny, including advertising violations or research integrity concerns.
Financial and reputational consequences
Penalties for mishandling gender identity data can be severe. Under GDPR, fines may reach up to 4% of a company’s global revenue. In California, violations of the CPRA can cost up to $7,500 per incident. Regulators may also impose corrective actions, such as ongoing audits or data protection impact assessments.
Litigation poses another major risk. Class actions can demand extensive discovery, exposing internal emails, vendor contracts, and other sensitive documents. Many companies settle to avoid reputational damage, even when they believe they acted properly.
Media coverage of mishandled data can be damaging. Environmental, social, and governance investors monitor how companies treat marginalized groups, and activist campaigns can amplify minor missteps. In clinical research, where participants expect anonymity, sponsors who share data with authorities without challenge may lose trust with patients.
Related: Common Mistakes People Make After a Slip and Fall in a Public Place
Investor and board scrutiny adds pressure. During mergers or acquisitions, weak data governance can be flagged as a material risk. Whistleblowers or employee advocates may raise concerns that disrupt deals or trigger disputes later.
Trust is a critical asset for these companies. Patients, trial participants, and regulators expect transparency and respect. A single error can damage confidence for years.
Best practices for managing gender identity data
To reduce these risks, companies should handle gender identity data with the same care as medical or biometric information. Key steps include:
- Data mapping and classification: Identify where gender identity data is collected, stored, and used, and label it as high-risk.
- Purpose limitation and consent: Obtain clear consent for collection and any additional uses, especially in marketing. Explain why the data is needed and how it will be used.
- Access controls: Limit who can access the data and track its usage. Anonymization or encryption can provide additional protection.
- Vendor oversight: Ensure contracts with third parties restrict data use, enforce deletion requirements, and allow for audits. Extend these obligations to subcontractors.
- Correction and inclusion: Let participants update their gender identity information and offer options for nonbinary or self-described identities.
- Transparency: Update privacy notices to explain why gender identity data is collected and how it’s shared.
- Audits and DPIAs: Conduct regular privacy impact assessments focused on risks related to this data.
- Training and governance: Educate clinical, marketing, and IT teams on handling sensitive data. Establish a privacy governance committee to oversee these efforts.
For life sciences firms, gender identity data represents more than a compliance challenge. With regulators, plaintiffs’ attorneys, and investors watching closely, the cost of mistakes can be high.
Companies expanding into new markets must also consider how local laws affect data collection. For example, firms entering Germany must handle additional privacy requirements that could impact their practices.
